0001437749-19-011280.txt : 20190603
0001437749-19-011280.hdr.sgml : 20190603
20190603164354
ACCESSION NUMBER: 0001437749-19-011280
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20190603
DATE AS OF CHANGE: 20190603
EFFECTIVENESS DATE: 20190603
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Diffusion Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001053691
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300645032
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-341007
FILM NUMBER: 19873838
BUSINESS ADDRESS:
STREET 1: 2020 AVON COURT
STREET 2: SUITE 4
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
BUSINESS PHONE: (434) 220-0718
MAIL ADDRESS:
STREET 1: 2020 AVON COURT
STREET 2: SUITE 4
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
FORMER COMPANY:
FORMER CONFORMED NAME: RestorGenex Corp
DATE OF NAME CHANGE: 20140307
FORMER COMPANY:
FORMER CONFORMED NAME: Stratus Media Group, Inc
DATE OF NAME CHANGE: 20080722
FORMER COMPANY:
FORMER CONFORMED NAME: FERIS INTERNATIONAL, INC.
DATE OF NAME CHANGE: 20080228
D
1
primary_doc.xml
X0708
D
LIVE
0001053691
Diffusion Pharmaceuticals Inc.
1317 CARLTON AVENUE
SUITE 200
CHARLOTTESVILLE
VA
VIRGINIA
22902
(434) 220-0718
DELAWARE
None
RestorGenex Corp
Stratus Media Group, Inc
FERIS INTERNATIONAL, INC.
Corporation
true
David
G.
Kalergis
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Executive Officer
Director
Mark
T.
Giles
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Director
John
L.
Gainer
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Executive Officer
Director
Robert
W.
Adams
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Director
Alan
G.
Levin
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Director
William
K.
Hornung
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Executive Officer
Thomas
S.
Byrne
1317 Carlton Avenue
Suite 200
Charlottesville
VA
VIRGINIA
22902
Executive Officer
Pharmaceuticals
Decline to Disclose
- 06b
false
2019-05-23
false
true
true
false
0
H.C. Wainwright & Co., LLC
375
None
None
430 Park Avenue
4th Floor
New York
NY
NEW YORK
10022
All States
true
164132
164132
0
false
3
13131
true
0
H.C. Wainwright & Co., LLC will also receive a 5-year warrant to purchase up to 65,853 shares of common stock.
0
A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.
true
Diffusion Pharmaceuticals Inc.
/s/ David G. Kalergis
David G. Kalergis
Chairman and CEO
2019-06-03